- Home
- NCDL vs MDXG Comparison
NCDL vs MDXG Comparison
Compare NCDL & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- MDXG
- Stock Information
- Founded
- NCDL 2019
- MDXG 2006
- Country
- NCDL United States
- MDXG United States
- Employees
- NCDL N/A
- MDXG N/A
- Industry
- NCDL
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- NCDL
- MDXG Health Care
- Exchange
- NCDL NYSE
- MDXG Nasdaq
- Market Cap
- NCDL 937.5M
- MDXG 1.1B
- IPO Year
- NCDL N/A
- MDXG N/A
- Fundamental
- Price
- NCDL $16.94
- MDXG $9.22
- Analyst Decision
- NCDL Buy
- MDXG Strong Buy
- Analyst Count
- NCDL 6
- MDXG 5
- Target Price
- NCDL $18.33
- MDXG $12.00
- AVG Volume (30 Days)
- NCDL 155.2K
- MDXG 1.1M
- Earning Date
- NCDL 11-07-2024
- MDXG 10-30-2024
- Dividend Yield
- NCDL 5.28%
- MDXG N/A
- EPS Growth
- NCDL N/A
- MDXG N/A
- EPS
- NCDL N/A
- MDXG 0.52
- Revenue
- NCDL N/A
- MDXG $342,804,000.00
- Revenue This Year
- NCDL N/A
- MDXG $9.56
- Revenue Next Year
- NCDL N/A
- MDXG $9.19
- P/E Ratio
- NCDL N/A
- MDXG $17.84
- Revenue Growth
- NCDL N/A
- MDXG 10.93
- 52 Week Low
- NCDL $16.00
- MDXG $5.47
- 52 Week High
- NCDL $18.10
- MDXG $9.49
- Technical
- Relative Strength Index (RSI)
- NCDL 44.35
- MDXG 79.76
- Support Level
- NCDL $16.94
- MDXG $8.55
- Resistance Level
- NCDL $17.24
- MDXG $9.49
- Average True Range (ATR)
- NCDL 0.23
- MDXG 0.42
- MACD
- NCDL 0.01
- MDXG 0.17
- Stochastic Oscillator
- NCDL 30.00
- MDXG 89.66
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.